期刊文献+

COPD和AECOPD住院患者病原菌分离情况和耐药分析 被引量:14

Distribution and drug resistant of pathogens in hospitalized patients of COPD and AECOPD
下载PDF
导出
摘要 目的观察慢性阻塞性肺病(COPD)和慢性阻塞性肺疾病急性加重(AECOPD)病原菌的分布情况及耐药特点,为临床合理用药提供依据。方法回顾分析华西医院2010年1—12月1860例检出病原菌的COPD和AECOPD患者的病原菌分布,标本来源,科别及耐药性。结果 COPD和AECOPD患者病原菌主要从痰标本检出(87%,95%)。COPD患者多为老年科患者(38%),而AECOPD多为呼吸科(39%)。以革兰阴性杆菌为主(79.5%,88.3%),前3位是:不动杆菌属(21.4%,34.7%)、假单胞菌属(19.1%,20.6%)和克雷伯菌属(14.6%,10.9%)。AECOPD患者鲍曼不动杆菌的耐药性显著高于COPD患者,铜绿假单胞菌耐药率相似,但肺炎克雷伯菌对哌拉西林的耐药性COPD组显著高于AECOPD组。结论 COPD患者和AECOPD患者病原菌分布相似但耐药性有所差异,临床应根据药敏结果选用抗生素。 Objective To observe the distribution and drug resistant of pathogens in hospitalized patients of chronic obstructive pulmonary disease (COPD) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD), so as to offer guidance reasonable clinical use of antibiotics. Methods Analysing pathogen distribution, specimen types, departments and drug resistance of 1860 COPD and AECOPD patients in West China Hospital from Jan 2010 to Dec 2014 by retrospective analysis. Results Sputum was the most common specimen (87%, 95%). The COPD patients were mainly in the department of geriatrics (38%), while AECOPD patients were mainly in the department of respiration (39%). The main pathogens isolated from COPD and AECOPD patients were gram negative bacilli (88.3%, 79.5%, P〈0.05), the topthree included: Acinetobacter (21.4%, 34.7%), Pseudomonas aeruginosa (19.1%, 20.6%) and Klebsiella pneumoniae (14.6%, 10.9%). The drug resistance rate of Acinetobacter baumanii of AECOPD patients was significantly higher than those of patients with COPD. The rate of Pseudomonas aeruginosa was similar, and the drug resistance rate of Klebsiella pneumonia was significantly higher in AECOPD patients than in COPD patients. Conclusion The pathogens isolated from COPD patients and AECOPD patients were similar in distribution but vary in drug resistance, so the clinical use of antibiotics should be based on the results of drug sensitivity.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2015年第12期954-958,共5页 Chinese Journal of Antibiotics
基金 国家自然科学基金(No.81000712)
关键词 COPD AECOPD 病原菌 耐药性 Chronic obstructive pulmonary diseases Acute exacerbation of chronic obstructive pulmonary disease Pathogens Drug resistance
  • 相关文献

参考文献8

二级参考文献43

共引文献735

同被引文献131

  • 1黄俊芳,王广发.慢性阻塞性肺病全球倡议慢性阻塞性肺病指南(2013更新版)解读[J].中国医学前沿杂志(电子版),2013,5(3):58-60. 被引量:60
  • 2刘剑,罗志扬,张培芳.雾化吸入高剂量表面激素与全身静脉激素治疗高龄AECOPD患者的疗效对比[J].广州医学院学报,2014,42(2):39-42. 被引量:4
  • 3Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations [J] . Lung India, 2013, 30 (3): 228 267. DOI: 10. 4103/0970-2113. 116248.
  • 4Verduri A, Luppi F, D'amico R, et al. Antibiotic treatment of severe exacerbations of chronic ohstructive pulmonary disease with procaleitonin:a randomized noninferiority trial[ J]. PLoS One, 2015, 10 (3): e0118241. DOI: 10. 1371/journal. pone. 0118241.
  • 5Daubin C, Parienti J J, Fradin S, et al. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study[J]. BMC Infect Dis,2009,9(l):157 FINI.ln 11o/.
  • 6Daubin C, Parienti JJ, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study[J]. BMC Infect Dis, 2008, 8(1):145. DOI: 10.1186/1471-2334-8-145.
  • 7Kutz A, Briel M, Christ-Crain M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings[J]. Crit Care, 2015, 19 (1): 74. DOI: 10. 1186/ s13054-015-0792-1.
  • 8Schuetz P, Christ-Crain M, Wolbers M, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial[J]. BMC Health Serv Res, 2007,7 (1) : 102. DOI : 10. 1186/1472-6963-7-102.
  • 9Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections:an individual patient data meta-analysis [j]. Clin Infect Dis, 2012,55(5) : 651-662. DOh 10. 1093/cid/ cis464.
  • 10何威,徐刚,张承,等.小剂量心脏选择性p受体阻滞剂在AECOPD合并右心功能衰竭患者中的安全性及疗效评价[J].中国急救医学,2015,35(z2):10-11.

引证文献14

二级引证文献146

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部